曼恩凯德生物医疗 MNKD 深 沪
等待开盘 07-08 09:30:00 美东时间
4.22
-0.050
-1.17%
华盛通- 最 高4.4057
- 今 开4.33
- 成交量 339.41万股
- 最 低 4.16
- 昨 收 4.27
- 总市值 13.04亿
- 52周最高 6.51
- 市盈率 静 225.67
- 换手率 1.10%
- 52周最低 2.23
- 委 比 -58.88%
- 总股本 3.09亿
- 历史最高 57.40
- 量 比 0.64
- 振 幅 5.75%
- 历史最低 0.666
- 每 手 1
- 风险率 1.19%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多MannKind Awarded Grant From Breakthrough T1D To Support Ongoing INHALE-1ST Clinical Study Evaluating Initiation Of Afrezza Inhalation Powder Shortly After Type 1 Diabetes Diagnosis In Pediatric Patients
Collaboration underscores interest in inhaled insulin and strengthens bringing innovation and new options to pediatric diabetes care DANBURY, Conn. and WESTLAKE VILLAGE, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), a company focused on the development and commercia...
06-23 21:03
MannKind Awarded Breakthrough T1D Grant to Support Advancement of INHALE-1ST Pediatric Trial of Afrezza® in Youth with Newly-Diagnosed T1D
MannKind Corporation has received a grant from Breakthrough T1D to support the INHALE-1ST clinical study evaluating Afrezza, an inhaled insulin, in pediatric patients newly diagnosed with type 1 diabetes. The study assesses the safety and efficacy of Afrezza combined with basal insulin in youth aged 10 to 18. This collaboration highlights growing interest in advancing inhaled insulin as a new therapeutic option for pediatric diabetes care.
06-23 13:00
Jim Cramer Puts This Chip Stock In The 'Penalty Box,' Warns Occidental Could 'Go Down A Lot' If War Ends
Cramer put Photronics in the penalty box due to poor results. He praised Woodward and warned against Occidental Petroleum.
06-05 20:05
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Option Care Health (OPCH)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
06-01 18:20
MannKind To Present New Clinical And Real‑World Data On Afrezza Inhalation Powder And Analyses Of Furoscix In Patients With Co-Morbidities At The American Diabetes Association's 2026 Scientific Sessions, June 5-8
MannKind Corporation (NASDAQ:MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced
05-27 21:08
MannKind to Present at Jefferies Global Healthcare Conference
MannKind Corporation announced that CEO Michael Castagna will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET. A live audio webcast and a recorded version will be available on MannKind's website. MannKind is a biopharmaceutical company focused on developing innovative treatments for chronic diseases, including diabetes and pulmonary hypertension, with expertise in drug-device combination...
05-27 20:00
MannKind director Steven B. Binder disposes of 22,500 shares worth $75,927.40
MannKind director Steven B. Binder disposes of 22,500 shares worth $75,927.40 Steven B. Binder, director, cut stake in MannKind to 808,008 common shares following transactions dated May 11-12. Disposed of 16,940 shares at USD 3.29 under a Rule 10b5-1 plan. Withheld 5,560 shares at USD 3.52 to cover
05-14 08:30
美股大行评级 | 绩后暴跌10%，ARM仍获高盛、富国银行等多家大行上调目标价；康宁、优步、飞塔信息、西维斯、Agilon Health等获多家大行上调目标价
今日重点评级关注：Citizens：维持BioCryst制药"跑赢大市"评级，目标价从25美元升至28美元；富国银行：维持曼恩凯德生物医疗"超配"评级，目标价从8美元升至10美元
05-08 12:05
MannKind Leans Into Growth Amid Earnings Volatility
MannKind Corporation (($MNKD)) has held its Q1 earnings call. Read on for the m...
05-08 10:17
Mizuho Maintains Outperform on MannKind, Lowers Price Target to $7
Mizuho analyst Anthony Petrone maintains MannKind (NASDAQ:MNKD) with a Outperform and lowers the price target from $8 to $7.
05-07 20:39
